Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
- Novartis Institutes for BioMedical Research, United States
- Novartis Institutes for BioMedical Research, Switzerland
- Genomics Institute of the Novartis Research Foundation, United States
Peer review process
This article was accepted for publication via eLife's original publishing model. eLife publishes the authors' accepted manuscript as a PDF only version before the full Version of Record is ready for publication. Peer reviews are published along with the Version of Record.
History
- Version of Record published
- Accepted Manuscript published
- Accepted
- Received
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
eLife 6:e17137.
https://doi.org/10.7554/eLife.17137
